Display options
Cite
Oidor-Chan VH, Hong E, Pérez-Severiano F, et al. Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model. PPAR Res. 2016;2016:8237264doi: 10.1155/2016/8237264.
Oidor-Chan, V. H., Hong, E., Pérez-Severiano, F., Montes, S., Torres-Narváez, J. C., Del Valle-Mondragón, L., Pastelín-Hernández, G., & Sánchez-Mendoza, A. (2016). Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model. PPAR research, 20168237264. https://doi.org/10.1155/2016/8237264
Oidor-Chan, Víctor Hugo, et al. "Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model." PPAR research vol. 2016 (2016): 8237264. doi: https://doi.org/10.1155/2016/8237264
Oidor-Chan VH, Hong E, Pérez-Severiano F, Montes S, Torres-Narváez JC, Del Valle-Mondragón L, Pastelín-Hernández G, Sánchez-Mendoza A. Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model. PPAR Res. 2016;2016:8237264. doi: 10.1155/2016/8237264. Epub 2016 Mar 16. PMID: 27069466; PMCID: PMC4812489.
Copy Download .nbib Format: NLM
Share it on

PPAR Res. 2016;2016:8237264. doi: 10.1155/2016/8237264. Epub 2016 Mar 16.

Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model.

PPAR research

Víctor Hugo Oidor-Chan, Enrique Hong, Francisca Pérez-Severiano, Sergio Montes, Juan Carlos Torres-Narváez, Leonardo Del Valle-Mondragón, Gustavo Pastelín-Hernández, Alicia Sánchez-Mendoza

Affiliations

  1. Department of Pharmacobiology, Research and Advanced Studies Center, National Polytechnic Institute (IPN), Calzada de los Tenorios No. 235, Colonia Granjas Coapa, Tlalpan, 14330 Mexico City, Mexico; Department of Pharmacology, National Institute of Cardiology Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, Tlalpan, 14080 Mexico City, Mexico.
  2. Department of Pharmacobiology, Research and Advanced Studies Center, National Polytechnic Institute (IPN), Calzada de los Tenorios No. 235, Colonia Granjas Coapa, Tlalpan, 14330 Mexico City, Mexico.
  3. Department of Neurochemistry, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Insurgentes Sur No. 3877, Colonia La Fama, Tlalpan, 14269 Mexico City, Mexico.
  4. Department of Pharmacology, National Institute of Cardiology Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, Tlalpan, 14080 Mexico City, Mexico.

PMID: 27069466 PMCID: PMC4812489 DOI: 10.1155/2016/8237264

Abstract

We investigated whether fenofibrate, metformin, and their combination generate cardioprotection in a rat model of type 2 diabetes (T2D) and acute myocardial infarction (AMI). Streptozotocin-induced diabetic- (DB-) rats received 14 days of either vehicle, fenofibrate, metformin, or their combination and immediately after underwent myocardial ischemia/reperfusion (I/R). Fenofibrate plus metformin generated cardioprotection in a DBI/R model, reported as decreased coronary vascular resistance, compared to DBI/R-Vehicle, smaller infarct size, and increased cardiac work. The subchronic treatment with fenofibrate plus metformin increased, compared with DBI/R-Vehicle, total antioxidant capacity, manganese-dependent superoxide dismutase activity (MnSOD), guanosine triphosphate cyclohydrolase I (GTPCH-I) expression, tetrahydrobiopterin : dihydrobiopterin (BH4 : BH2) ratio, endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) bioavailability, and decreased inducible NOS (iNOS) activity. These findings suggest that PPARα activation by fenofibrate + metformin, at low doses, generates cardioprotection in a rat model of T2D and AMI and may represent a novel treatment strategy to limit I/R injury in patients with T2D.

References

  1. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):445-50 - PubMed
  2. J Am Coll Cardiol. 2004 Apr 21;43(8):1481-8 - PubMed
  3. Diabetes. 2009 Aug;58(8):1893-901 - PubMed
  4. Pharmacology. 2007;80(2-3):177-84 - PubMed
  5. FEBS Lett. 2001 Aug 3;502(3):98-102 - PubMed
  6. Endocrinology. 2006 Dec;147(12):5967-74 - PubMed
  7. Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H276-82 - PubMed
  8. Basic Res Cardiol. 2006 May;101(3):244-52 - PubMed
  9. Circ Heart Fail. 2010 Jan;3(1):125-31 - PubMed
  10. Eur J Pharmacol. 2012 Jun 15;685(1-3):108-15 - PubMed
  11. J Clin Endocrinol Metab. 2003 Apr;88(4):1637-45 - PubMed
  12. Am J Physiol. 1985 Feb;248(2 Pt 2):H179-85 - PubMed
  13. Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15081-6 - PubMed
  14. FASEB J. 2002 Jul;16(9):1027-40 - PubMed
  15. Methods Enzymol. 1984;105:93-104 - PubMed
  16. Cardiovasc Res. 2002 Sep;55(4):838-49 - PubMed
  17. Basic Res Cardiol. 2008 May;103(3):274-84 - PubMed
  18. J Biol Chem. 2000 Jun 2;275(22):16638-42 - PubMed
  19. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15401-6 - PubMed
  20. Biomed Res Int. 2014;2014:193095 - PubMed
  21. Integr Blood Press Control. 2010;3:125-32 - PubMed
  22. J Mol Cell Cardiol. 2006 Aug;41(2):318-29 - PubMed
  23. J Mol Endocrinol. 1999 Feb;22(1):1-8 - PubMed
  24. Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H719-27 - PubMed
  25. J Cardiovasc Pharmacol. 2009 May;53(5):373-8 - PubMed
  26. Cardiovasc Res. 2011 Jul 15;91(2):340-9 - PubMed
  27. Diabetes Obes Metab. 2007 Nov;9(6):869-78 - PubMed
  28. Am J Physiol Regul Integr Comp Physiol. 2007 Mar;292(3):R1184-9 - PubMed
  29. J Cardiovasc Pharmacol. 2012 Oct;60(4):323-34 - PubMed
  30. Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d - PubMed
  31. PPAR Res. 2011;2011:523520 - PubMed
  32. Circulation. 2003 Nov 11;108(19):2393-9 - PubMed
  33. Pharmacol Rep. 2013;65(1):208-13 - PubMed
  34. Ann Intern Med. 1999 Aug 17;131(4):281-303 - PubMed
  35. Clin Sci (Lond). 2002 Aug;103 Suppl 48:284S-288S - PubMed
  36. Diabetes Metab Syndr Obes. 2013 Apr 11;6:151-60 - PubMed
  37. Curr Opin Pharmacol. 2013 Apr;13(2):161-7 - PubMed
  38. J Mol Med (Berl). 2014 May;92(5):441-52 - PubMed
  39. BMC Cancer. 2014 Feb 16;14:96 - PubMed
  40. J Immunol. 2001 Jun 15;166(12 ):7543-8 - PubMed
  41. Eur Rev Med Pharmacol Sci. 2014;18(15):2205-14 - PubMed
  42. Diabetes. 2008 Mar;57(3):696-705 - PubMed
  43. Int J Mol Sci. 2012;13(6):7694-709 - PubMed
  44. Pharmacol Rep. 2013;65(2):429-34 - PubMed
  45. Diabetes Care. 2013 Aug;36 Suppl 2:S162-74 - PubMed

Publication Types